Published in Ther Adv Musculoskelet Dis on October 01, 2013
Risk of atypical femoral fracture during and after bisphosphonate use. Acta Orthop (2015) 1.11
Treatment of primary osteoporosis in men. Clin Interv Aging (2014) 0.84
Factors associated with atypical femoral fracture. Rheumatol Int (2015) 0.81
Association between bone mineral density and clinical consequences: cross-sectional study of Korean postmenopausal women in an orthopaedic outpatient clinic. J Korean Med Sci (2014) 0.79
Efficacy of bisphosphonates against osteoporosis in adult men: a meta-analysis of randomized controlled trials. Osteoporos Int (2015) 0.75
Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med (2007) 9.83
Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med (2005) 8.32
World-wide projections for hip fracture. Osteoporos Int (1997) 6.83
Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med (2009) 6.67
Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N Engl J Med (1994) 6.59
The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med (2003) 5.45
Incidence of clinically diagnosed vertebral fractures: a population-based study in Rochester, Minnesota, 1985-1989. J Bone Miner Res (1992) 4.75
Clinical practice. Osteoporosis in men. N Engl J Med (2008) 3.91
Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol (2003) 3.82
Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med (2001) 3.78
Fracture risk and zoledronic acid therapy in men with osteoporosis. N Engl J Med (2012) 3.51
Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev (2008) 3.45
Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. J Clin Endocrinol Metab (1995) 3.34
The prevalence of vertebral deformity in european men and women: the European Vertebral Osteoporosis Study. J Bone Miner Res (1996) 3.25
Effects of sex and age on bone microstructure at the ultradistal radius: a population-based noninvasive in vivo assessment. J Bone Miner Res (2005) 3.11
Alendronate for the treatment of osteoporosis in men. N Engl J Med (2000) 3.11
A population-based assessment of rates of bone loss at multiple skeletal sites: evidence for substantial trabecular bone loss in young adult women and men. J Bone Miner Res (2008) 2.76
Normal, bound and nonbound testosterone levels in normally ageing men: results from the Massachusetts Male Ageing Study. Clin Endocrinol (Oxf) (2005) 2.63
Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial. Ann Intern Med (2007) 2.54
The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res (2003) 2.50
Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. J Clin Endocrinol Metab (1996) 2.30
Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev (2008) 2.00
Cost-effectiveness of fracture prevention in men who receive androgen deprivation therapy for localized prostate cancer. Ann Intern Med (2010) 1.84
Incidence of hip and other osteoporotic fractures in elderly men and women: Dubbo Osteoporosis Epidemiology Study. J Bone Miner Res (2004) 1.79
Osteonecrosis of the jaw--do bisphosphonates pose a risk? N Engl J Med (2006) 1.74
Risk factors for osteoporotic fractures in elderly men. Am J Epidemiol (1996) 1.70
Effect of testosterone replacement on trabecular architecture in hypogonadal men. J Bone Miner Res (2005) 1.67
Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy. Osteoporos Int (2004) 1.57
Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study. J Bone Miner Res (2010) 1.54
Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate. J Clin Endocrinol Metab (2008) 1.53
Efficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study. Rheumatol Int (2005) 1.52
Progressive loss of bone in the femoral neck in elderly people: longitudinal findings from the Dubbo osteoporosis epidemiology study. BMJ (1994) 1.51
Association of testosterone and estradiol deficiency with osteoporosis and rapid bone loss in older men. J Clin Endocrinol Metab (2006) 1.44
Bone loss in men with prostate cancer treated with gonadotropin-releasing hormone agonists. J Clin Endocrinol Metab (2001) 1.42
Osteoporosis in men. Endocr Rev (1995) 1.41
Osteoporosis in men treated with androgen deprivation therapy for prostate cancer. J Urol (2002) 1.39
Epidemiology and clinical features of osteoporosis in young individuals. Bone (1995) 1.31
Does alendronate reduce the risk of fracture in men? A meta-analysis incorporating prior knowledge of anti-fracture efficacy in women. BMC Musculoskelet Disord (2005) 1.27
Osteoporosis in men with idiopathic hypogonadotropic hypogonadism. Ann Intern Med (1987) 1.23
Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study. J Bone Miner Res (2009) 1.22
Clinical review 123: Anabolic therapy for osteoporosis. J Clin Endocrinol Metab (2001) 1.21
Bone fragility in men--where are we? Osteoporos Int (2006) 1.19
Prevalent vertebral deformities: relationship to bone mineral density and spinal osteophytosis in elderly men and women. Osteoporos Int (1996) 1.08
Bone and metabolic health in patients with non-metastatic prostate cancer who are receiving androgen deprivation therapy. Med J Aust (2011) 1.05
The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide [human parathyroid hormone(1-34)]. Osteoporos Int (2004) 1.05
Effects of transdermal testosterone gel on bone turnover markers and bone mineral density in hypogonadal men. Clin Endocrinol (Oxf) (2001) 1.04
Efficacy and safety of monthly ibandronate in men with low bone density. Bone (2010) 1.04
Early and rapid bone mineral density loss of the proximal femur in men. J Clin Endocrinol Metab (2007) 1.00
Osteoporosis in men. New insights into aetiology, pathogenesis, prevention and management. Drugs Aging (1998) 0.93
Once-weekly oral alendronate 70 mg in patients with glucocorticoid-induced bone loss: a 12-month randomized, placebo-controlled clinical trial. J Rheumatol (2009) 0.88
Observations on nursing home residents with a history of hip fracture. Am J Med Sci (1995) 0.88
Biochemical markers of bone turnover in men. Calcif Tissue Int (2001) 0.87
Longitudinal study of calcium metabolism in male puberty. II. Relationship between mineralization and serum testosterone. Acta Paediatr Scand (1984) 0.84
Bisphosphonates and glucocorticoid-induced osteoporosis: efficacy and tolerability. Joint Bone Spine (2012) 0.83
Bone turnover markers and sex hormones in men with idiopathic osteoporosis. Eur J Clin Invest (2001) 0.83
Cost effectiveness of alendronate for the treatment of male osteoporosis in Sweden. Bone (2004) 0.78
Some skeletal dimensions of males with isolated gonadotrophin deficiency. Neth J Med (1992) 0.76
A randomized trial of vertebroplasty for painful osteoporotic vertebral fractures. N Engl J Med (2009) 11.20
Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res (2007) 6.76
Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res (2010) 6.00
Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res (2013) 5.76
Vitamin D and health in adults in Australia and New Zealand: a position statement. Med J Aust (2012) 3.14
Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab (2012) 2.87
Is high dose vitamin D harmful? Calcif Tissue Int (2012) 2.43
Vitamin D and musculoskeletal health, cardiovascular disease, autoimmunity and cancer: Recommendations for clinical practice. Autoimmun Rev (2010) 2.38
Vitamin D deficiency is associated with tuberculosis and latent tuberculosis infection in immigrants from sub-Saharan Africa. Clin Infect Dis (2008) 2.10
Serum 25-hydroxyvitamin D, calcium intake, and risk of type 2 diabetes after 5 years: results from a national, population-based prospective study (the Australian Diabetes, Obesity and Lifestyle study). Diabetes Care (2011) 1.67
Preventing osteoporosis: outcomes of the Australian Fracture Prevention Summit. Med J Aust (2002) 1.59
Association of cartilage defects with loss of knee cartilage in healthy, middle-age adults: a prospective study. Arthritis Rheum (2005) 1.49
Low serum 25-hydroxyvitamin D is associated with increased risk of the development of the metabolic syndrome at five years: results from a national, population-based prospective study (The Australian Diabetes, Obesity and Lifestyle Study: AusDiab). J Clin Endocrinol Metab (2012) 1.45
Prevalence of vitamin D deficiency and its determinants in Australian adults aged 25 years and older: a national, population-based study. Clin Endocrinol (Oxf) (2012) 1.43
Effects of denosumab on fracture and bone mineral density by level of kidney function. J Bone Miner Res (2011) 1.40
Reduced serum total osteocalcin is associated with metabolic syndrome in older men via waist circumference, hyperglycemia, and triglyceride levels. Eur J Endocrinol (2010) 1.39
14th Vitamin D Workshop consensus on vitamin D nutritional guidelines. J Steroid Biochem Mol Biol (2010) 1.20
Changes in bone turnover and bone loss in HIV-infected patients changing treatment to tenofovir-emtricitabine or abacavir-lamivudine. PLoS One (2012) 1.14
Approach to the patient with secondary osteoporosis. Eur J Endocrinol (2010) 1.08
Routine screening for vitamin D deficiency in early pregnancy: past its due date? Med J Aust (2011) 1.08
Randomized controlled trial of the effects of calcium with or without vitamin D on bone structure and bone-related chemistry in elderly women with vitamin D insufficiency. J Bone Miner Res (2008) 1.05
Improving diagnosis of tumor-induced osteomalacia with Gallium-68 DOTATATE PET/CT. J Clin Endocrinol Metab (2013) 1.04
Efficacy and safety of vertebroplasty for treatment of painful osteoporotic vertebral fractures: a randomised controlled trial [ACTRN012605000079640]. BMC Musculoskelet Disord (2008) 1.02
The effects of soy protein containing isoflavones on lipids and indices of bone resorption in postmenopausal women. Clin Endocrinol (Oxf) (2003) 0.99
Central abdominal fat and endogenous hormones during the menopausal transition. Fertil Steril (2003) 0.98
An atypical subtrochanteric femoral fracture from pycnodysostosis: a lesson from nature. J Bone Miner Res (2011) 0.96
Effects of a targeted multimodal exercise program incorporating high-speed power training on falls and fracture risk factors in older adults: a community-based randomized controlled trial. J Bone Miner Res (2014) 0.95
Effect of vitamin D supplementation on antibiotic use: a randomized controlled trial. Am J Clin Nutr (2013) 0.93
The effect of acute exercise on undercarboxylated osteocalcin and insulin sensitivity in obese men. J Bone Miner Res (2014) 0.93
Environmental, personal, and genetic determinants of response to vitamin D supplementation in older adults. J Clin Endocrinol Metab (2014) 0.93
The relationship between body composition and knee cartilage volume in healthy, middle-aged subjects. Arthritis Rheum (2005) 0.92
Vitamin D deficiency and its role in muscle-bone interactions in the elderly. Curr Osteoporos Rep (2014) 0.91
Higher serum undercarboxylated osteocalcin and other bone turnover markers are associated with reduced diabetes risk and lower estradiol concentrations in older men. J Clin Endocrinol Metab (2015) 0.90
Secondary causes of low bone mass in patients with breast cancer: a need for greater vigilance. J Clin Oncol (2009) 0.90
Myelosuppressive therapies significantly increase pro-inflammatory cytokines and directly cause bone loss. J Bone Miner Res (2015) 0.90
Osteo-cise: strong bones for life: protocol for a community-based randomised controlled trial of a multi-modal exercise and osteoporosis education program for older adults at risk of falls and fractures. BMC Musculoskelet Disord (2012) 0.89
Efficacy and safety of oral continuous low-dose versus short-term high-dose vitamin D: a prospective randomised trial conducted in a clinical setting. Med J Aust (2010) 0.89
Sarcopenic obesity and dynapenic obesity: 5-year associations with falls risk in middle-aged and older adults. Obesity (Silver Spring) (2014) 0.88
The relative effect of endogenous estradiol and androgens on menopausal bone loss: a longitudinal study. Osteoporos Int (2004) 0.88
Declining incidence of osteoporotic hip fracture in Australia. Arch Osteoporos (2012) 0.88
Lack of sustained response to teriparatide in a patient with adult hypophosphatasia. J Clin Endocrinol Metab (2010) 0.86
25-Hydroxyvitamin D levels and chronic kidney disease in the AusDiab (Australian Diabetes, Obesity and Lifestyle) study. BMC Nephrol (2012) 0.86
Serum 25-hydroxyvitamin D deficiency and the 5-year incidence of CKD. Am J Kidney Dis (2013) 0.86
Oral health risk factors for bisphosphonate-associated jaw osteonecrosis. J Oral Maxillofac Surg (2013) 0.86
Frequent walking, but not total physical activity, is associated with increased fracture incidence: a 5-year follow-up of an Australian population-based prospective study (AusDiab). J Bone Miner Res (2011) 0.85
Cord blood-derived macrophage-lineage cells rapidly stimulate osteoblastic maturation in mesenchymal stem cells in a glycoprotein-130 dependent manner. PLoS One (2013) 0.84
Relationship between bone markers and knee cartilage volume in healthy men. J Rheumatol (2005) 0.84
Intravenous zoledronate improves bone density in adults with cystic fibrosis (CF). Clin Endocrinol (Oxf) (2008) 0.84
Predicting vitamin D deficiency in older Australian adults. Clin Endocrinol (Oxf) (2013) 0.83
Determinants of change in patella cartilage volume in healthy subjects. J Rheumatol (2006) 0.82
Reference intervals for bone turnover markers and their association with incident hip fractures in older men: the Health in Men study. J Clin Endocrinol Metab (2015) 0.82
Treatment for osteoporosis in Australian residential aged care facilities: consensus recommendations for fracture prevention. Med J Aust (2010) 0.82
Is excess calcium harmful to health? Nutrients (2010) 0.81
Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg (2008) 0.81
Two-year results of a randomized placebo-controlled trial of vertebroplasty for acute osteoporotic vertebral fractures. J Bone Miner Res (2014) 0.81
Vitamin d and physical activity status: associations with five-year changes in body composition and muscle function in community-dwelling older adults. J Clin Endocrinol Metab (2014) 0.81
Prospective evaluation of a protocol for reduced glucocorticoid replacement in transsphenoidal pituitary adenomectomy: prophylactic glucocorticoid replacement is seldom necessary. Clin Endocrinol (Oxf) (2008) 0.81
A sample preparation protocol for 1H nuclear magnetic resonance studies of water-soluble metabolites in blood and urine. Anal Biochem (2009) 0.80
Megadose therapy for vitamin D deficiency. Med J Aust (2005) 0.80
What is the clinical and ethical importance of incidental abnormalities found by knee MRI? Arthritis Res Ther (2008) 0.80
Vitamin D Deficiency May Be Associated with a More Rapid Decline in CD4 Cell Count to <350 Cells/µL in Untreated HIV-Infected Adults. Curr HIV Res (2015) 0.80
Exercise as an intervention to improve metabolic outcomes after intrauterine growth restriction. Am J Physiol Endocrinol Metab (2014) 0.79
Shining the light on Sunshine: a systematic review of the influence of sun exposure on type 2 diabetes mellitus-related outcomes. Clin Endocrinol (Oxf) (2014) 0.79
Measurements of 25-hydroxyvitamin D concentrations in archived dried blood spots are reliable and accurately reflect those in plasma. J Clin Endocrinol Metab (2014) 0.79
Serum selenium status in Graves' disease with and without orbitopathy: a case-control study. Clin Endocrinol (Oxf) (2014) 0.79
Ultraviolet index and location are important determinants of vitamin D status in people with human immunodeficiency virus. Photochem Photobiol (2014) 0.79
Vitamin D, muscle function, and falls in older adults: does reduced deposition of intramuscular adipose tissue influence the relationship? J Clin Endocrinol Metab (2013) 0.79
Osteoporosis in men: its pathophysiology and the role of teriparatide in its treatment. Clin Interv Aging (2008) 0.78
Population rates of bone densitometry use in Australia, 2001-2005, by sex and rural versus urban location. Med J Aust (2009) 0.78
Social determinants of bone densitometry uptake for osteoporosis risk in patients aged 50yr and older: a systematic review. J Clin Densitom (2012) 0.78
Editorial: inhibin in bone--new tricks for an old dog. J Clin Endocrinol Metab (2006) 0.78
Defective osteoblast function may be responsible for bone loss from the proximal femur despite pamidronate therapy. J Clin Endocrinol Metab (2005) 0.77
Fall and Fracture Risk in Sarcopenia and Dynapenia With and Without Obesity: the Role of Lifestyle Interventions. Curr Osteoporos Rep (2015) 0.77
What is the missing hormonal factor controlling menopausal bone resorption? J Clin Endocrinol Metab (2010) 0.77
Associations between socioeconomic status and primary total knee joint replacements performed for osteoarthritis across Australia 2003-10: data from the Australian Orthopaedic Association National Joint Replacement Registry. BMC Musculoskelet Disord (2014) 0.77
(1)H-NMR analysis of the human urinary metabolome in response to an 18-month multi-component exercise program and calcium-vitamin-D3 supplementation in older men. Appl Physiol Nutr Metab (2014) 0.77
Suburban clustering of vitamin D deficiency in Melbourne, Australia. Asia Pac J Clin Nutr (2008) 0.76
Recruitment and results of a pilot trial of vitamin D supplementation in the general population of Australia. J Clin Endocrinol Metab (2012) 0.76
Vitamin D deficiency is common in HIV-infected southern Australian adults. Antivir Ther (2015) 0.76
Recent advances in managing osteoporosis. F1000 Med Rep (2009) 0.75
Metabolic bone diseases: translational research-preventing fractures with denosumab. Nat Rev Rheumatol (2009) 0.75
Positive effects of intravenous zoledronic acid on bone remodeling and structure: are different effects on osteoblast activity to other oral bisphosphonates responsible? J Bone Miner Res (2008) 0.75
Is high-dose vitamin d harmful? Authors' reply. Calcif Tissue Int (2013) 0.75
A Single Dose of Prednisolone as a Modulator of Undercarboxylated Osteocalcin and Insulin Sensitivity Post-Exercise in Healthy Young Men: A Study Protocol. JMIR Res Protoc (2016) 0.75
Myxoedema and a lost wedding ring. Med J Aust (2003) 0.75
When continuity of care breaks down: a systems failure in identification of osteoporosis risk in older patients treated for minimal trauma fractures. Med J Aust (2008) 0.75
Decreased spinal and femoral neck volumetric bone mineral density (BMD) in men with primary osteoporosis and their first-degree male relatives: familial effect on BMD in men. Clin Endocrinol (Oxf) (2007) 0.75
Development of a wearable plantar force measurement device for gait analysis in remote conditions. Conf Proc IEEE Eng Med Biol Soc (2017) 0.75
An elusive phaeochromocytoma. Med J Aust (2011) 0.75
The birth of Bone Reports. Bone Rep (2015) 0.75